Education
About Us
Working with TipRanks
Follow Us
Adicet Bio (GB:0HX7)
LSE:0HX7
0HX7 Stock Chart & Stats
$7.42
-$0.08(-7.54%)
At close: 4:00 PM EST
$7.42
-$0.08(-7.54%)
Day’s Range― - ―
52-Week Range$6.50 - $22.40
Previous CloseN/A
Volume2.90K
Average Volume (3M)25.58K
Market Cap
$69.44M
Enterprise Value$55.88M
Total Cash (Recent Filing)$103.10M
Total Debt (Recent Filing)$15.54M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Mar 05, 2026EPS Estimate
-2.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.64
Shares Outstanding9,578,474
10 Day Avg. Volume22,377
30 Day Avg. Volume25,580
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.90
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.52
Forecast
1Y Price Target
$29.33Price Target Upside295.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-33.73
Revenue Forecast (FY)$2.86M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyEarly clinical data show ADI-001 and prula-cel produced strong renal responses, including complete renal remissions and sustained reductions in lupus disease activity, indicating meaningful efficacy potential versus peers.
Regulatory Pathway And Trial DesignAnalyst notes that the company plans to request an FDA meeting and initiate a pivotal lupus nephritis trial with a design expected to align with peer programs, which could support regulatory comparability and streamline the approval pathway.
Safety And TolerabilityClinical reports indicate a benign safety profile with the CD20-targeting CAR gamma-delta T cells and prula-cel that enabled reductions in corticosteroid use and the prospect of outpatient dosing, improving practical use compared with many competitors.
Bears Say
Listing Risk And Capital StructureImplementation of a reverse stock split to maintain the exchange listing altered the capital structure and signals listing pressure, which may raise investor concern about liquidity and governance stability.
Share DilutionA recent large share issuance caused meaningful dilution, prompting reassessment of valuation and reducing existing shareholders' ownership stakes.
Valuation And Program RiskAnalysts adopted more conservative valuation assumptions by lowering success probabilities and increasing discounting of future cash flows, reflecting higher perceived program risk and exerting downward pressure on price targets.
Adicet Bio News
0HX7 FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest share price was $6.50 and its highest was $22.40 in the past 12 months.
What is Adicet Bio’s market cap?
Adicet Bio’s market cap is $69.44M.
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is Mar 05, 2026 which is in 4 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on Nov 05, 2025. The company reported -$4.64 earnings per share for the quarter, missing the consensus estimate of -$4.639 by >-$0.001.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Adicet Bio dividends here
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -2.91.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 9,578,474 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -$4.64 in its last earnings report, missing expectations of -$4.639. Following the earnings report the stock price went down -2.296%.
Which hedge fund is a major shareholder of Adicet Bio?
Currently, no hedge funds are holding shares in GB:0HX7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.00%
12-Months-Change
Fundamentals
Return on Equity
-71.73%
Trailing 12-Months
Asset Growth
-42.89%
Trailing 12-Months
Company Description
Adicet Bio
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
0HX7 Stock 12 Month Forecast
Average Price Target
$29.33
▲(295.28% Upside)
Technical Analysis
Sutro Biopharma
―
PMV Pharmaceuticals
―
Gain Therapeutics
―
Immix Biopharma
―
Artiva Biotherapeutics, Inc.
―